{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:18:54Z","timestamp":1762431534701},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T00:00:00Z","timestamp":1534464000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s12149-018-1287-3","type":"journal-article","created":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T07:59:41Z","timestamp":1534492781000},"page":"658-668","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Diagnostic performance of 11C-choline PET\/CT and FDG PET\/CT for staging and restaging of renal cell cancer"],"prefix":"10.1007","volume":"32","author":[{"given":"Yukako","family":"Nakanishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Kitajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiko","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuken","family":"Go","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Kanematsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michio","family":"Nojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Yamakado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,17]]},"reference":[{"key":"1287_CR1","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.eururo.2015.01.005","volume":"67","author":"B Ljungberg","year":"2015","unstructured":"Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, et al. Guidelines on renal cell carcinoma. Eur Urol. 2015;67:913\u201324.","journal-title":"Eur Urol"},{"issue":"Suppl 3","key":"1287_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/annonc\/mdu259","volume":"25","author":"B Escudier","year":"2014","unstructured":"Escudier B, Porta C, Schmidinger M, Algaba F, Patard JJ, Khoo V, et al. ESMO Guidelines Working Group. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):49\u201356.","journal-title":"Ann Oncol"},{"key":"1287_CR3","first-page":"395","volume":"6","author":"MC Smaldone","year":"2012","unstructured":"Smaldone MC, Chen DY, Yu JQ, Plimack ER. Potential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer. Biologics. 2012;6:395\u2013407.","journal-title":"Biologics"},{"key":"1287_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40644-015-0049-x","volume":"15","author":"KP Horn","year":"2015","unstructured":"Horn KP, Yap JT, Agarwal N, Morton KA, Kadrmas DJ, Beardmore B, et al. FDG and FLT-PET for early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma. Cancer Imaging. 2015;15:15.","journal-title":"Cancer Imaging"},{"key":"1287_CR5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s13139-011-0084-x","volume":"45","author":"N Oyama","year":"2011","unstructured":"Oyama N, Takahara N, Hasegawa Y, Tanase K, Miwa Y, Akino H, et al. Assessment of therapeutic effect of sunitinib by 11C-Acetate PET compared with FDG PET imaging in a patient with metastatic renal cell carcinoma. Nucl Med Mol Imaging. 2011;45:217\u201319.","journal-title":"Nucl Med Mol Imaging"},{"key":"1287_CR6","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s12149-010-0375-9","volume":"24","author":"M Middendorp","year":"2010","unstructured":"Middendorp M, Maute L, Sauter B, Vogl TJ, Gr\u00fcnwald F. Initial experience with 18F-fluoroethylcholine PET\/CT in staging and monitoring therapy response of advanced renal cell carcinoma. Ann Nucl Med. 2010;24:441\u20136.","journal-title":"Ann Nucl Med"},{"key":"1287_CR7","first-page":"273","volume":"79","author":"K Kitajima","year":"2017","unstructured":"Kitajima K, Fukushima K, Yamamoto S, Kato T, Odawara S, Takaki H, et al. 11C-Choline positive but 18F-FDG negative pancreatic metastasis from renal cell carcinoma on PET. Nagoya J Med Sci. 2017;79:273\u20137.","journal-title":"Nagoya J Med Sci"},{"key":"1287_CR8","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.2967\/jnumed.110.084517","volume":"52","author":"F Hugonnet","year":"2011","unstructured":"Hugonnet F, Fournier L, Medioni J, Smadja C, Hindi\u00e9 E, Huchet V, et al. Hypoxia in Renal Cancer Multicenter Group: metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month\u2019s sunitinib, and therapeutic response: an 18F-fluoromisonidazole PET\/CT study. J Nucl Med. 2011;52:1048\u201355.","journal-title":"J Nucl Med"},{"key":"1287_CR9","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s11307-009-0220-5","volume":"11","author":"DM Schuster","year":"2009","unstructured":"Schuster DM, Nye JA, Nieh PT, Votaw JR, Halkar RK, Issa MM, et al. Initial experience with the radiotracer anti-1amino-3-[18F]fluorocyclobutane-1-carboxylic acid (anti-[18F] FACBC) with PET in renal carcinoma. Mol Imaging Biol. 2009;11:434\u20138.","journal-title":"Mol Imaging Biol"},{"key":"1287_CR10","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/1754-9485.12590","volume":"61","author":"S Siva","year":"2017","unstructured":"Siva S, Callahan J, Pryor D, Martin J, Lawrentschuk N, Hofman MS. Utility of 68Ga prostate specific membrane antigen - positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma. J Med Imaging Radiat Oncol. 2017;61:372\u20138.","journal-title":"J Med Imaging Radiat Oncol"},{"key":"1287_CR11","doi-asserted-by":"crossref","first-page":"10156","DOI":"10.1016\/S0021-9258(19)50213-7","volume":"267","author":"T Uchida","year":"1992","unstructured":"Uchida T, Yamashita S. Molecular cloning, characterization, and expression in Escherichia coli of a cDNA encoding mammalian choline kinase. J Biol Chem. 1992;267:10156\u201362.","journal-title":"J Biol Chem"},{"key":"1287_CR12","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s11604-016-0553-3","volume":"34","author":"K Kitajima","year":"2016","unstructured":"Kitajima K, Yamamoto S, Fukushima K, Minamimoto R, Kamai T, Jadvar H. Update on advances in molecular PET in urological oncology. Jpn J Radiol. 2016;34:470\u201385.","journal-title":"Jpn J Radiol"},{"key":"1287_CR13","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S0969-8043(98)00097-9","volume":"50","author":"T Hara","year":"1999","unstructured":"Hara T, Yuasa M. Automated synthesis of [11C]choline, a positron-emitting tracer for tumor imaging. Appl Radiat Isot. 1999;50:531\u20133.","journal-title":"Appl Radiat Isot"},{"key":"1287_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ejrad.2009.11.019","volume":"79","author":"K Nakatani","year":"2011","unstructured":"Nakatani K, Nakamoto Y, Saga T, Higashi T, Togashi K. The potential clinical value of FDG-PET for recurrent renal cell carcinoma. Eur J Radiol. 2011;79:29\u201335.","journal-title":"Eur J Radiol"},{"key":"1287_CR15","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s00259-015-3159-6","volume":"43","author":"P Alongi","year":"2016","unstructured":"Alongi P, Picchio M, Zattoni F, Spallino M, Gianolli L, Saladini G, et al. Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2016;43:464\u201373.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1287_CR16","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1097\/01.ju.0000120241.50061.e4","volume":"171","author":"DE Kang","year":"2004","unstructured":"Kang DE, White RL Jr, Zuger JH, Sasser HC, Teigland CM. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol. 2004;171:1806\u20139.","journal-title":"J Urol"},{"key":"1287_CR17","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/MNM.0b013e32833d6882","volume":"31","author":"R Kumar","year":"2010","unstructured":"Kumar R, Shandal V, Shamim SA, Jeph S, Singh H, Malhotra A. Role of FDG PET-CT in recurrent renal cell carcinoma. Nucl Med Commun. 2010;31:844\u201350.","journal-title":"Nucl Med Commun"},{"key":"1287_CR18","doi-asserted-by":"crossref","first-page":"e320-4","DOI":"10.1097\/RLU.0000000000000382","volume":"39","author":"C Fuccio","year":"2014","unstructured":"Fuccio C, Ceci F, Castellucci P, Spinapolice EG, Palumbo R, D\u2019Ambrosio D, et al. Restaging clear cell renal carcinoma with 18F-FDG PET\/CT. Clin Nucl Med. 2014;39:e320-4.","journal-title":"Clin Nucl Med"},{"key":"1287_CR19","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/MNM.0000000000000618","volume":"38","author":"H Ma","year":"2017","unstructured":"Ma H, Shen G, Liu B, Yang Y, Ren P, Kuang A. Diagnostic performance of 18F-FDG PET or PET\/CT in restaging renal cell carcinoma: a systematic review and meta-analysis. Nucl Med Commun. 2017;38:156\u201363.","journal-title":"Nucl Med Commun"},{"key":"1287_CR20","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1102\/1470-7330.2012.0042","volume":"12","author":"HY Wang","year":"2012","unstructured":"Wang HY, Ding HJ, Chen JH, Chao CH, Lu YY, Lin WY, et al. Meta-analysis of the diagnostic performance of [18F]FDGPET and PET\/CT in renal cell carcinoma. Cancer Imaging. 2012;12:464\u201374.","journal-title":"Cancer Imaging"},{"key":"1287_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1046\/j.1442-2042.2002.00416.x","volume":"9","author":"H Miyakita","year":"2002","unstructured":"Miyakita H, Tokunaga M, Onda H, Usui Y, Kinoshita H, Kawamura N, et al. Significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer. Int J Urol. 2002;9:15\u20138.","journal-title":"Int J Urol"},{"key":"1287_CR22","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1007\/s00259-003-1211-4","volume":"30","author":"N Aide","year":"2003","unstructured":"Aide N, Cappele O, Bottet P, Bensadoun H, Regeasse A, Comoz F, et al. Efficiency of [18F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging. 2003;30:1236\u201345.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1287_CR23","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1200\/JCO.2003.04.073","volume":"21","author":"NS Majhail","year":"2003","unstructured":"Majhail NS, Urbain JL, Albani JM, Kanvinde MH, Rice TW, Novick AC, et al. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol. 2003;21:3995\u20134000.","journal-title":"J Clin Oncol"},{"key":"1287_CR24","doi-asserted-by":"publisher","first-page":"4866","DOI":"10.1007\/s00330-017-4875-z","volume":"27","author":"R Nakajima","year":"2017","unstructured":"Nakajima R, Nozaki S, Kondo T, Nagashima Y, Abe K, Sakai S. Evaluation of renal cell carcinoma histological subtype and Fuhrman grade using 18F-fluorodeoxyglucose-positron emission tomography\/computed tomography. Eur Radiol. 2017;27:4866\u201373.","journal-title":"Eur Radiol"},{"key":"1287_CR25","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1124\/dmd.118.081091","volume":"46","author":"M Visentin","year":"2018","unstructured":"Visentin M, Torozi A, Gai Z, H\u00e4usler S, Li C, Hiller C, et al. Fluorocholine transport mediated by the organic cation transporter 2 (OCT2, SLC22A2): implication for imaging of kidney tumors. Drug Metab Dispos. 2018;46:1129\u201336.","journal-title":"Drug Metab Dispos"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12149-018-1287-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-018-1287-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-018-1287-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T15:43:02Z","timestamp":1661787782000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12149-018-1287-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,17]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1287"],"URL":"https:\/\/doi.org\/10.1007\/s12149-018-1287-3","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,17]]},"assertion":[{"value":"19 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"We declare no financial support or relationship that may pose conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"We clearly state that human participants have the approval of an appropriate named ethics committee including Helsinki declaration. We declare no financial support or relationship that may pose conflict of interest. The authors confirm that this manuscript has not been published or presented elsewhere, in part or in entirety, and is not under consideration by any other journal. All authors have made substantial contributions to this work and have read and approved the final submitted version.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}